Your Source for Venture Capital and Private Equity Financings

Boundless Bio Raises $105M Series B

2021-04-28
SAN DIEGO, Boundless Bio announced the closing of an oversubscribed $105 Million Series B financing co-led by RA Capital and Nextech.
Boundless Bio, a precision oncology company, announced the closing of an oversubscribed $105 Million Series B financing.

Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.

RA Capital Management and Nextech Invest co-led the financing, with participation from a top-tier syndicate of funds, including Fidelity Management & Research Company, Redmile Group, Wellington Management, Surveyor Capital (a Citadel company), PFM Health Sciences, and Logos Capital.

Current investors ARCH Venture Partners, City Hill Ventures, Vertex Ventures HC, GT Healthcare Capital Partners, Boxer Capital of Tavistock Group, and Alexandria Venture Investments also participated in the Series B.
(c)2011-2020 by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000 startups and 5,000 VC investors


Featured Reading